A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 11/17/2010

Posted by | 10:20pm on Wednesday, November 17, 2010

:
Welcome to the marketing & social media pharma chat (#socpharm). I am your host tonight Xavier Petit #socpharm

:
Hi Xavier, so nice to be a guest tonight & have you in the driver’s seat! #socpharm

:
the basics: We?ll assume that all tweets within #socpharm are your own and not your employers (unless otherwise specified) #socpharm

:
thanks for having me! #socpharm

:
My tweets are certainly my own #socpharm

:
. @ looking forward to the #socpharm chat!

:
a little abt me I work in pharma (shire) & I have a great interest in emerging media (are they really emerging) including SM #socpharm

:
Specifically very interested on how can pharma enter the SM space and what value we can provide #socpharm

:
We?ll get to this topic but first thing first.T1 one is related to regulatory are you ready? #socpharm

:
Hi there– looking forward to tonight’s discussion :) #socpharm

:
Ready! #socpharm

:
Was @ a conference today and again. An agency stated that pharma is afraid of sm because of Adverse Event? #socpharm

:
so there it is: Is pharma afraid of SM because of AE reporting and specificially because pharma does no want to report them? #socpharm

:
I have my opinion on that but before I start, any thoughts out there? #socpharm

:
@ Gr8 question. I know I’ve heard @ state that AEs are the big red herring. Easy for pharma to blame to avoid sm. #socpharm

:
RT @: so there it is: Is pharma afraid of SM because of AE reporting and specificially because pharma does no want to report them? #socpharm

:
Certainly SM should tie back into AE reporting mechanisms that exist, but it’s an easy excuse. Others? #socpharm

:
Our clients had concerns about monitoring SM chats, forums, etc b/c of AEs. So yes, @ from my experience there is fear. #socpharm

:
However unfounded….#socpharm

:
agreed.. it has to be a consideration and be addressed. #socpharm

:
thanks pr_in_pinks… I am sure that it is indeed a concern but is it the main reason? #socpharm

:
Heard from @ that she’s working on update to seminal AE research in SM #socpharm

:
Interesting, as the information on AEs points to a very small # reported on SM to date #socpharm

:
absolutely @ #socpharm

:
@ SM is still the elephant in the room for pharma and an excuse, but not the main reason. #socpharm

:
@ yes. AER is just too much to ask of pharma. Especially when it endangers them. They’re incentivized against it. #socpharm

:
agree on that to @ #socpharm

:
@ Which is such a shame… #socpharm

:
Can’t wait to see new data RT @ Heard from @ that she’s working on update to seminal AE research in SM #socpharm

:
@. Not sure that’s the real issue here. if you want to report you can regardless of SM no? #socpharm

:
Is the other issue lack of tactical ROI, where #sm may encourage ROR (return on relationship)? #socpharm

:
@ Canada MSWatch.ca recently shut down because they had drug mentions including some AE’s. Decided not to monitor / edit #socpharm

:
My opinion is that pharma is not afraid of AE. Pharma is afraid of DDMAC and regulators rightfully so #socpharm

:
With no clarity of liability, responsibility isn’t engaging on one platform creating a precedent? Let me clarify #socpharm

:
That’s it! RT @: My opinion is that pharma is not afraid of AE. Pharma is afraid of DDMAC and regulators rightfully so #socpharm

:
leads me to T2: Does engaging on a sm platform create a precedent and therefore requires to then monitor this platform forever? #socpharm

:
Ex: if as a pharma co I correct an entry on Wikipedia? Am I liable to correct all content regarding my products? Forever? #socpharm

:
@ I think if you own the platform then you should monitor it for as long as you own it. In terms of Wikipedia, no. #socpharm

:
@: very interesting comments… I think your onto something..we’ll adress this in T3 #socpharm

:
agreed on ownership and liability… but still not sure about the other. I struggle with that one #socpharm

:
T2 If pharma were monitoring the #SM space, wouldn’t they want to correct bad info if they were able? But not be held liable #socpharm

:
T2: SM is an investment of time. If you start it, you should grow it and maintain it. Pharma isn’t an exception. #socpharm

:
PR_in_Pink :) yes that’s it. let’s call is a night! aha (i know that was simplistic) #socpharm

:
T2 on platforms they do not own as @ stated #socpharm

:
Wikipedia is a interesting case. All you can do is try to correct bad info & present useful/neutral info. #socpharm

:
There’s a difference of long terms for relationship (user experience) and regulatory liability though #socpharm

:
what is the status of limitation for SM? no guidelines… #socpharm

:
Some pharma seems afraid of commitment, too. #socpharm

:
Is the liability question really how many times does pharma have to monitor and address/fix the same issue on the same platform? #socpharm

:
@ that a great point. Some are afraid. some are not even aware of it… #socpharm

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

One Pingback/Trackback

    19 November 2010 at 6:11pm
    Posted #socpharm transcript w/guest ...
  • Eileen O'Brien
Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com